检索临床试验

该平台协议设计灵活，适用于卫生保健系统内的各种环境, 远程设置, 在皇冠hga020电脑版环境中，可将其纳入COVID-19规划和后续治疗计划.

This protocol is a prospective, 多中心, 多臂机, 随机, controlled platform trial evaluating potential interventions for PASC-mediated cognitive dysfunction. The hypothesis is that PASC associated dysfunction in cognitive domains, such as executive function and attention, may be improved by interventions that selectively focus on enhancing those domains.

COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. 该试验旨在确定与安慰剂+ SOC(安慰剂组)相比，在病程早期(患者接受低流量供氧时)加强阿巴接受(活性组)联合标准护理(SOC)是否能改善康复。. 对于两组人来说, 如果出现疾病进展迹象(患者需要高流量鼻氧(HFNO)或更多支持)和/或患者需氧量迅速增加，将作为SOC的一部分提供强化免疫调节.

这项研究正在进行，以确定甲磺酸cenicriviroc (CVC)是否会减少血管炎症，这是通过18f -氟脱氧葡萄糖(FDG)-主动脉正电子发射断层扫描(PET)/计算机断层扫描(CT)成像测量的.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive 癌症中心's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, 一种针对呼吸道合胞病毒(RSV)和人偏肺病毒(hMPV)及其mRNA-1345的mRNA疫苗, an mRNA vaccine targeting RSV, in participants aged 5 months to <24 months.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive 癌症中心's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

Treatments are needed to improve outcomes among patients hospitalized for COVID-19, 包括直接作用抗病毒药物(DAA)，以减轻由正在进行的病毒复制驱动的病理. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. 有限公司.

The study design is a 随机, 安慰剂对照, 多中心国际临床试验，将评估在标准护理(SOC)之外给予ensitrelvir治疗COVID-19住院患者的临床疗效. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.

这是一项随机安慰剂对照研究，在年龄≥40岁且已知CVD或1个CVD危险因素的治疗和抑制hiv感染者中研究苯戊酸(BA)对安全性的影响, arterial 炎症 as assessed by FDG-PET/CT, 脂质, 炎症, 免疫激活, 代谢疾病指数, and non-calcified plaque (NCP) in the coronary arteries (assessed by coronary CT angiography, CCTA). This trial will be enrolled at UCSF and UCLA. Collaborators at Massachusetts General Hospital (MGH) will serve as the core facility for imaging.

The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. 该研究还将评估SLGN刺激TLR8是否会降低血液中乙型肝炎表面抗原(HBsAg)滴度.

A5418是随机的, 安慰剂对照, 开展双盲研究，以确定替可维林对实验室确诊或推定HMPXV疾病患者的治疗效果.

A5418是随机的, 安慰剂对照, 开展双盲研究，以确定替可维林对实验室确诊或推定HMPXV疾病患者的治疗效果.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive 癌症中心's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive 癌症中心's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

The current pilot study will recruit participants experiencing new, 返回, 或在首次感染SARS-CoV-2后至少四周内出现与COVID-19疾病相关的持续症状. 所有参与者都将参加一个名为“正念意识练习”(MAPs)的虚拟课程，为期6周, 由皇冠hga025大学洛杉矶分校正念意识研究中心(MARC)的专家主持和领导，. This intervention will consist of a mix of lecture, 实践, 集团的反馈, and discussion regarding mindfulness. 正念是一种精神状态，通过将一个人的意识集中在现在，同时承认和接受任何感觉, 的想法, 或者身体感觉. The research team will collect self-reported measures of mental health symptoms, 身体健康症状, and demographic information before and after participants attend MAPs. Objective health measures will also be collected by the research team including an active stand test, 步行6分钟, 还有血液样本.

本研究的目的是确定强力霉素是否会减少艾滋病毒感染者肺气肿的进展.

The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, 步行6分钟, 患者报告的结果, ratio of forced expiratory volume in 1 second and forced vital capacity. 次要目标还将描述强力霉素的安全性和耐受性，并确定强力霉素是否与抗生素耐药细菌感染的发展有关.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive 癌症中心's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

The purpose of this clinical trial is to learn about the safety, 药代动力学(药代动力学帮助我们了解服药后药物是如何变化和从体内排出的), 研究药物(称为nirmatrelvir/ritonavir)用于潜在治疗2019冠状病毒病(COVID-19)的疗效(研究治疗在研究中的效果).

该研究药物将用于18岁以下未住院但有严重疾病风险的COVID-19患者.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive 癌症中心's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.